Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.Annals of hematology · 2026Pooled it
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.Transplantation and cellular therapy · 2024Guideline
- Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.Blood research · 2026Review
- Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.Blood advances · 2026Article
- Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.Nature communications · 2026Article
- Vaccination should not be forgotten in patients receiving immunoglobulin replacement therapy.Blood advances · 2026Article
- Vaccination Against Respiratory Infections in Adults with Cancer: A Concise Guide for Clinicians.Vaccines · 2026Review
- Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review.Frontiers in medicine · 2026Review
- Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.Frontiers in medicine · 2026Review
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Review
- CAR T cell therapy for children with rheumatic disease: the time is now.Nature reviews. Rheumatology · 2025Review
- Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.Blood cancer journal · 2025Article
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy.Transplantation and cellular therapy · 2025Article
- Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.Nature reviews. Clinical oncology · 2025Review
- Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.Infectious diseases and therapy · 2025Review
- Vaccines for Use in Special Populations: Immunocompromised Hosts.The Journal of infectious diseases · 2025Article
- Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy, and safety.Clinical and experimental immunology · 2025Review
- Mitigating and managing infection risk in adults treated with CAR T-cell therapy.Hematology. American Society of Hematology. Education Program · 2024Review
Corrections and comments
- Update of
Authors and funding
30 authors.
Funding
Abstract
backgroundThe optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether humoral and cellular responses after SARS-CoV-2 vaccination differ if initiated <4 months versus 4-12 months after cellular therapy.
methodsWe conducted a multicenter, prospective, observational study at 30 cancer centers in the United States. SARS-CoV-2 vaccination was administered as part of routine care. We obtained blood prior to and after vaccinations at up to 5 time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T-cell receptors, in a subgroup.
resultsWe enrolled 466 allogeneic hematopoietic cell transplantation (HCT) (n = 231), autologous HCT (n = 170), and chimeric antigen receptor T-cell (CAR-T-cell) therapy (n = 65) recipients between April 2021 and June 2022. Humoral and cellular responses did not significantly differ among participants initiating vaccinations <4 months versus 4-12 months after cellular therapy. Anti-S IgG ≥2500 U/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T-cell recipients, respectively. SARS-CoV-2-specific T-cell responses were attained in 57%, 83%, and 58%, respectively. Pre-cellular therapy SARS-CoV-2 infection or vaccination and baseline B-cell count were key predictors of post-cellular therapy immunity.
conclusionsThese data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation 3 to 4 months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.